Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q2294895> ?p ?o }
Showing triples 1 to 34 of
34
with 100 triples per page.
- Q2294895 subject Q7211373.
- Q2294895 abstract "Small modular immunopharmaceuticals, or SMIPs for short, are artificial proteins that are intended for use as pharmaceutical drugs. They are largely built from parts of antibodies (immunoglobulins), and like them have a binding site for antigens that could be used for monoclonal antibody therapy. SMIPs have similar biological half-life and, being smaller than antibodies, are reasoned to have better tissue penetration properties. They were invented by Trubion and are now being developed by Emergent BioSolutions, which acquired Trubion in 2010.".
- Q2294895 thumbnail Small_modular_immunopharmaceutical.svg?width=300.
- Q2294895 wikiPageWikiLink Q103537.
- Q2294895 wikiPageWikiLink Q1088156.
- Q2294895 wikiPageWikiLink Q12140.
- Q2294895 wikiPageWikiLink Q1429031.
- Q2294895 wikiPageWikiLink Q14906101.
- Q2294895 wikiPageWikiLink Q15315373.
- Q2294895 wikiPageWikiLink Q1616930.
- Q2294895 wikiPageWikiLink Q170050.
- Q2294895 wikiPageWikiLink Q17163357.
- Q2294895 wikiPageWikiLink Q187255.
- Q2294895 wikiPageWikiLink Q208414.
- Q2294895 wikiPageWikiLink Q284398.
- Q2294895 wikiPageWikiLink Q290671.
- Q2294895 wikiPageWikiLink Q310425.
- Q2294895 wikiPageWikiLink Q3776943.
- Q2294895 wikiPageWikiLink Q5370757.
- Q2294895 wikiPageWikiLink Q56646.
- Q2294895 wikiPageWikiLink Q616005.
- Q2294895 wikiPageWikiLink Q626251.
- Q2294895 wikiPageWikiLink Q6589727.
- Q2294895 wikiPageWikiLink Q6901969.
- Q2294895 wikiPageWikiLink Q7211373.
- Q2294895 wikiPageWikiLink Q7847126.
- Q2294895 wikiPageWikiLink Q79448.
- Q2294895 wikiPageWikiLink Q79460.
- Q2294895 wikiPageWikiLink Q8054.
- Q2294895 wikiPageWikiLink Q949267.
- Q2294895 wikiPageWikiLink Q978273.
- Q2294895 comment "Small modular immunopharmaceuticals, or SMIPs for short, are artificial proteins that are intended for use as pharmaceutical drugs. They are largely built from parts of antibodies (immunoglobulins), and like them have a binding site for antigens that could be used for monoclonal antibody therapy. SMIPs have similar biological half-life and, being smaller than antibodies, are reasoned to have better tissue penetration properties.".
- Q2294895 label "Small modular immunopharmaceutical".
- Q2294895 depiction Small_modular_immunopharmaceutical.svg.